Butenafine

CHEMBL990 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
317.5 g/mol
LogP
6.3
Phase
4

A topical antifungal of the benzylamine class used to treat tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch). It works by inhibiting an enzyme in the fungal cell membrane synthesis pathway called squalene epoxidase, disrupting membrane integrity. It is available as a cream and requires consistent application for full effectiveness.

Masse moléculaire

317,5000 g/mol

LogP

6,30

TPSA

3,20 Ų

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12

InChI

InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3

Molecular Formula

C23H27N

HBD / HBA

- / 1

Liaisons Rotatives

5

Atomes Lourds

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A topical antifungal of the benzylamine class used to treat tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch). It works by inhibiting an enzyme in the fungal cell membrane synthesis pathway called squalene epoxidase, disrupting membrane integrity. It is available as a cream and requires consistent application for full effectiveness.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Butenafine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL990. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2484. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.